[{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt explores iNO as potential Covid-19 therapy\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Exicure","sponsor":"Bluejay","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Exicure"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the terms of the agreement, Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents including AST-008 (cavrotolimod), an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology applications.
Company published evidence suggesting a potential role of inhaled nitric oxide as a supportive measure in treating those patients infected with SARS-CoV-2 and having associated pulmonary difficulties.